AAAAAA

   
Results: 1-20 |
Results: 20
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity
Authors: Smith, PG Thomas, HD Barlow, HC Griffin, RJ Golding, BT Calvert, AH Newell, DR Curtin, NJ
Citation: Pg. Smith et al., In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity, CLIN CANC R, 7(7), 2001, pp. 2105-2113
A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer
Authors: Miles, DW Smith, IE Coleman, RE Calvert, AH Lind, MJ
Citation: Dw. Miles et al., A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer, EUR J CANC, 37(11), 2001, pp. 1366-1371
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer
Authors: Boddy, AV Griffin, MJ Sludden, J Thomas, HD Fishwick, K Wright, JG Plummer, ER Highley, M Calvert, AH
Citation: Av. Boddy et al., Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer, CANC CHEMOT, 48(1), 2001, pp. 15-21
Estimation of glomerular filtration rate in cancer patients
Authors: Wright, JG Boddy, AV Highley, M Fenwick, J McGill, A Calvert, AH
Citation: Jg. Wright et al., Estimation of glomerular filtration rate in cancer patients, BR J CANC, 84(4), 2001, pp. 452-459
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
Authors: Bowman, KJ Newell, DR Calvert, AH Curtin, NJ
Citation: Kj. Bowman et al., Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro, BR J CANC, 84(1), 2001, pp. 106-112
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
Authors: Delaney, CA Wang, LZ Kyle, S White, AW Calvert, AH Curtin, NJ Durkacz, BW Hostomsky, Z Newell, DR
Citation: Ca. Delaney et al., Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines, CLIN CANC R, 6(7), 2000, pp. 2860-2867
Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presenceof alpha(1)-acid glycoprotein (AGP)
Authors: Barlow, HC Bowman, KJ Curtin, NJ Calvert, AH Golding, BT Huang, B Loughlin, PJ Newell, DR Smith, PG Griffin, RJ
Citation: Hc. Barlow et al., Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presenceof alpha(1)-acid glycoprotein (AGP), BIOORG MED, 10(6), 2000, pp. 585-589
Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours
Authors: Thomas, HD Lind, MJ Ford, J Bleehen, N Calvert, AH Boddy, AV
Citation: Hd. Thomas et al., Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours, CANC CHEMOT, 45(4), 2000, pp. 284-290
Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine
Authors: Griffin, RJ Arris, CE Bleasdale, C Boyle, FT Calvert, AH Curtin, NJ Dalby, C Kanugula, S Lembicz, NK Newell, DR Pegg, AE Golding, BT
Citation: Rj. Griffin et al., Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine, J MED CHEM, 43(22), 2000, pp. 4071-4083
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase
Authors: White, AW Almassy, R Calvert, AH Curtin, NJ Griffin, RJ Hostomsky, Z Maegley, K Newell, DR Srinivasan, S Golding, BT
Citation: Aw. White et al., Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase, J MED CHEM, 43(22), 2000, pp. 4084-4097
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
Authors: Arris, CE Boyle, FT Calvert, AH Curtin, NJ Endicott, JA Garman, EF Gibson, AE Golding, BT Grant, S Griffin, RJ Jewsbury, P Johnson, LN Lawrie, AM Newell, DR Noble, MEM Sausville, EA Schultz, R Yu, W
Citation: Ce. Arris et al., Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles, J MED CHEM, 43(15), 2000, pp. 2797-2804
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel
Authors: Hughes, AN Griffin, MJ Newell, DR Calvert, AH Johnston, A Kerr, B Lee, C Liang, B Boddy, AV
Citation: An. Hughes et al., Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel, BR J CANC, 82(9), 2000, pp. 1519-1527
Clinical experience with cisplatin and carboplatin
Authors: Highley, MS Calvert, AH
Citation: Ms. Highley et Ah. Calvert, Clinical experience with cisplatin and carboplatin, CANC DRUG, 7, 2000, pp. 171-194
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days
Authors: Hughes, AN Rafi, I Griffin, MJ Calvert, AH Newell, DR Calvete, JA Johnston, A Clendeninn, N Boddy, AV
Citation: An. Hughes et al., Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days, CLIN CANC R, 5(1), 1999, pp. 111-118
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels
Authors: Ghazal-Aswad, S Tilby, MJ Lind, M Baily, N Sinha, DP Calvert, AH Newell, DR
Citation: S. Ghazal-aswad et al., Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels, ANN ONCOL, 10(3), 1999, pp. 329-334
Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growthinhibition by dipyridamole in human lung cancer cell lines
Authors: Smith, PG Marshman, E Calvert, AH Newell, DR Curtin, NJ
Citation: Pg. Smith et al., Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growthinhibition by dipyridamole in human lung cancer cell lines, SEMIN ONCOL, 26(2), 1999, pp. 63-67
Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene
Authors: Calvert, AH Ghokul, S Al-Azraqi, A Wright, J Lind, M Bailey, N Highley, M Siddiqui, N Lunec, J Sinha, D Boddy, A Roberts, F Fenwick, J
Citation: Ah. Calvert et al., Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene, SEMIN ONCOL, 26(1), 1999, pp. 90-94
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha(1)-acid glycoprotein binding
Authors: Curtin, NJ Bowman, KJ Turner, RN Huang, B Loughlin, PJ Calvert, AH Golding, BT Griffin, RJ Newell, DR
Citation: Nj. Curtin et al., Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha(1)-acid glycoprotein binding, BR J CANC, 80(11), 1999, pp. 1738-1746
Preclinical and clinical studies with the novel thymidylate synthase inhibitor nolatrexed dihydrochloride (Thymitaq (TM), AG337)
Authors: Hughes, A Calvert, AH
Citation: A. Hughes et Ah. Calvert, Preclinical and clinical studies with the novel thymidylate synthase inhibitor nolatrexed dihydrochloride (Thymitaq (TM), AG337), CANC DRUG, 1999, pp. 229-241
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
Authors: Griffin, RJ Srinivasan, S Bowman, K Calvert, AH Curtin, NJ Newell, DR Pemberton, LC Golding, BT
Citation: Rj. Griffin et al., Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), J MED CHEM, 41(26), 1998, pp. 5247-5256
Risultati: 1-20 |